Clinical Trial News and Research

RSS

Final data from Open-Label studies of Cinryze in patients with HAE now available

ViroPharma Incorporated today announced the availability of final data from Open-Label studies of Cinryze (C1 Esterase Inhibitor [Human]) in preventing and treating attacks of hereditary angioedema on the U.S. National Institutes of Health's online clinical trial registry, www.clinicaltrials.gov.

18 May 2010

Inovio Pharmaceuticals first-quarter net loss attributable to common stockholders decreases to $2.3M

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2010.

18 May 2010

Echo Therapeutics first-quarter net loss increases to $1.9 million

Echo Therapeutics, Inc., a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced financial results for the period ended March 31, 2010.

18 May 2010

Mpex Pharmaceuticals presents Phase 2b trial results of Aeroquin for cystic fibrosis at ATS Annual Meeting

Mpex Pharmaceuticals, Inc. today announced the presentation of data from its Phase 2b clinical trial with Aeroquin™ (a proprietary aerosol formulation of levofloxacin, MP-376) in cystic fibrosis (CF) at the American Thoracic Society (ATS) Annual Meeting in New Orleans.

17 May 2010

Aastrom Biosciences initiates treatment in Phase 2 catheter-based clinical trial for dilated cardiomyopathy

Aastrom Biosciences, Inc., the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that the first patient has been treated in the company's U.S. Phase 2 catheter-based clinical trial to treat dilated cardiomyopathy (DCM). Treatment was performed by interventional cardiologist Timothy D. Henry, M.D., FACC, at the Minneapolis Heart Institute® at Abbott Northwestern Hospital in Minneapolis, MN.

17 May 2010

Emisphere Technologies first-quarter net loss increases to $18.5 million

Emisphere Technologies, Inc. today announced its financial results for the first quarter 2010.

17 May 2010

ARCA biopharma announces SPA agreement with FDA for bucindolol clinical trial

ARCA biopharma, Inc. today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a clinical trial to assess the safety and efficacy of bucindolol in approximately 3,200 patients with chronic heart failure who have the genotype that appears to respond most favorably to bucindolol. Bucindolol is the Company's investigational, pharmacologically unique, beta-blocker and mild vasodilator.

17 May 2010

Soligenix first-quarter revenues decrease to $336,000

Soligenix, Inc., a late-stage biopharmaceutical company, announced today its financial results for the first quarter of 2010.

17 May 2010

Emergent BioSolutions' anthrax monoclonal antibody IND for Phase I study clears FDA review

Emergent BioSolutions Inc. announced today that its Investigational New Drug (IND) application, to commence a Phase I clinical trial for its anthrax monoclonal antibody therapeutic, has cleared U.S. Food and Drug Administration (FDA) review. The Phase I study will evaluate the safety and pharmacokinetics of the company's fully human monoclonal antibody being developed as a parenteral post-exposure therapy for individuals who have symptoms of anthrax disease. In pre-clinical therapeutic studies, Emergent's monoclonal antibody was found to be effective.

17 May 2010

Neovasc first-quarter revenues increase nearly 300% to $1.06 million

Neovasc Inc., today announced financial results for the three months ended March 31, 2009.

17 May 2010

Early CPAP as effective for preemies as ventilator, with fewer complications: Study

Two findings from an NIH research network study provide new information on how much oxygen very preterm infants should receive starting on the first day of life and the most effective means to deliver it to them.

17 May 2010

Athersys presents data supporting MultiStem programs

Athersys, Inc. today presented data supporting its MultiStem® programs in cardiovascular disease, neurological disease and immune system modulation, and highlighted advancements in other areas, including progress in its drug development program in the area of obesity.

15 May 2010

Protox announces positive top-line results from the TRIUMPH study in first quarter 2010

Protox Therapeutics Inc. a leader in the development of receptor targeted fusion proteins, today released financial results for the first quarter 2010, ended March 31, 2010. "The first quarter of 2010 marked significant achievements for the company, namely the announcement of positive top-line results from the TRIUMPH study and the subsequent completion of a five million dollar financing," said Dr. Fahar Merchant, President and CEO of Protox.

15 May 2010

New research facility at Riley Hospital for Children to improve clinical research trials for children

A new research facility at Riley Hospital for Children will dramatically improve the process of turning the results of laboratory research into new treatments for sick children, federal and local officials said Friday.

15 May 2010

Study examines safety of non-invasive cardiac shock wave procedure for angina pectoris

UC San Diego Health System is enrolling a small group of patients in a two-year study to examine the safety of a non-invasive cardiac shock wave procedure for patients with chest pain caused by insufficient blood flow to the heart.

15 May 2010

STOP AF trial: Arctic Front Cardiac CryoAblation Catheter System reduces AF symptoms by 80%

Medtronic, Inc. today released new STOP AF clinical trial data showing the number of paroxysmal atrial fibrillation patients reporting AF symptoms declined by 80 percent after treatment with the Arctic Front Cardiac CryoAblation Catheter System.

15 May 2010

BioMS reports consolidated net income of $6.5M for first-quarter 2010 compared to net loss of $3.8M in 2009

BioMS Medical Corp., today announced financial and operational results for the three months ended March 31, 2010.

15 May 2010

Nymox attributes increase in first-quarter net losses to higher clinical trial expenditures

Nymox Pharmaceutical Corporation announced today its financial results for the first quarter of 2010. Nymox reported a net loss of $1,269,550, or $0.04 per share for the quarter ending March 31, 2010, compared to $1,004,259, or $0.03 per share for same period in 2009. Net losses include stock compensation charges of $195,220 in 2010 and $309,650 in 2009.

14 May 2010

SANUWAVE Health reports $3.0 million net loss for first-quarter 2010

SANUWAVE Health, Inc.,, an emerging medical technology company focused on regenerative medicine, today reported financial results for the three months ended March 31, 2010 and provided a business update.

14 May 2010

BioSante Pharmaceuticals first-quarter net loss increases to $10.5 million

BioSante Pharmaceuticals, Inc. today reported on its recent developments and financial results for the first quarter, and its cash balance as of March 31, 2010.

14 May 2010

Clinical Trial News and Research

Final data from Open-Label studies of Cinryze in patients with HAE now available

Inovio Pharmaceuticals first-quarter net loss attributable to common stockholders decreases to $2.3M

Echo Therapeutics first-quarter net loss increases to $1.9 million

Mpex Pharmaceuticals presents Phase 2b trial results of Aeroquin for cystic fibrosis at ATS Annual Meeting

Aastrom Biosciences initiates treatment in Phase 2 catheter-based clinical trial for dilated cardiomyopathy

Emisphere Technologies first-quarter net loss increases to $18.5 million

ARCA biopharma announces SPA agreement with FDA for bucindolol clinical trial

Soligenix first-quarter revenues decrease to $336,000

Emergent BioSolutions' anthrax monoclonal antibody IND for Phase I study clears FDA review

Neovasc first-quarter revenues increase nearly 300% to $1.06 million

Early CPAP as effective for preemies as ventilator, with fewer complications: Study

Athersys presents data supporting MultiStem programs

Protox announces positive top-line results from the TRIUMPH study in first quarter 2010

New research facility at Riley Hospital for Children to improve clinical research trials for children

Study examines safety of non-invasive cardiac shock wave procedure for angina pectoris

STOP AF trial: Arctic Front Cardiac CryoAblation Catheter System reduces AF symptoms by 80%

BioMS reports consolidated net income of $6.5M for first-quarter 2010 compared to net loss of $3.8M in 2009

Nymox attributes increase in first-quarter net losses to higher clinical trial expenditures

SANUWAVE Health reports $3.0 million net loss for first-quarter 2010

BioSante Pharmaceuticals first-quarter net loss increases to $10.5 million

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer